DeepMed Research

PRGN-3007

Generic Name: PRGN-3007

Clinical Trials

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Phase 1

Active, not recruiting

Conditions: Diffuse Large B Cell Lymphoma
Triple Negative Breast Cancer Malignancies
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: PRGN-3007

First Posted Date: 2023-01-23

Last Posted Date: 2025-04-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 3

Registration Number: NCT05694364

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy